<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662090</url>
  </required_header>
  <id_info>
    <org_study_id>EWOG MDS 2006</org_study_id>
    <nct_id>NCT00662090</nct_id>
    <nct_alias>NCT00898339</nct_alias>
  </id_info>
  <brief_title>Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood</brief_title>
  <acronym>EWOG MDS 2006</acronym>
  <official_title>Prospective Non-randomized Multi-center Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to improve the accuracy of diagnosis for children and adolescents&#xD;
      with MDS by a standardized review of morphology and standardized cytogenetic and molecular&#xD;
      analysis.&#xD;
&#xD;
      The primary objectives of the study are:&#xD;
&#xD;
        -  To evaluate the frequency of the different subtypes of MDS in childhood and adolescence&#xD;
           by a standardized diagnostic approach&#xD;
&#xD;
        -  To evaluate the frequency of cytogenetic and molecular abnormalities:&#xD;
&#xD;
      Specifically using array-CGH to evaluate the frequency of subtle chromosomal imbalances, i.e.&#xD;
      gains and losses of defined chromosomal regions, and amplifications.&#xD;
&#xD;
      Specifically using mFISH to identify unknown chromosomal aberrations, particularly subtle&#xD;
      translocations involving new candidate genes, and to better define chromosomal breakpoints.&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To assess survival for children and adolescents with MDS and JMML&#xD;
&#xD;
        -  To evaluate relapse rate, morbidity and mortality in children with MDS and JMML treated&#xD;
           by HSCT&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the frequency of the different subtypes of MDS in childhood and adolescence by a standardized diagnostic approach</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the frequency of cytogenetic and molecular abnormalities</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess survival for children and adolescents with MDS and JMML</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate relapse rate, morbidity and mortality in children with MDS and JMML treated by HSCT</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At diagnosis, prior to HSCT and at relapse material form peripheral blood and bone marrow&#xD;
      will be retrieved and stored for research purposes. If there are other diagnostic bone marrow&#xD;
      examinations at other time points (prior to HSCT), the material will be handled the same way.&#xD;
&#xD;
      The following material will be retrieved:&#xD;
&#xD;
        -  8 smears from PB&#xD;
&#xD;
        -  8 smears from BM&#xD;
&#xD;
        -  at least 5 ml of heparinized PB&#xD;
&#xD;
        -  at least 5 ml of heparinized BM&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MDS and JMML diagnosted&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent by the caretakers and whenever possible the patient's assent.&#xD;
&#xD;
          -  Confirmed diagnosis of MDS or JMML (morphology, cytogenetics)&#xD;
&#xD;
          -  Myeloid leukemia of Down syndrome (patients aged &gt; 6 years).&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Denied informed consent and/or assent by caretakers/patient.&#xD;
&#xD;
          -  Myeloid leukemia of Down syndrome (patients &lt; 6 years).&#xD;
&#xD;
          -  Participation in another study within the last 4 weeks (except for therapy optimizing&#xD;
             studies in cancer or bone marrow failure disorders and studies in diagnostics).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>215 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte M. Niemeyer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Freiburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte M. Niemeyer, M.D.</last_name>
    <phone>49-761-270</phone>
    <phone_ext>45060</phone_ext>
    <email>charlotte.niemeyer@uniklinik-freiburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte M. Niemeyer, M.D.</last_name>
      <phone>49-761-270</phone>
      <phone_ext>4506</phone_ext>
      <email>charlotte.niemeyer@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Charlotte M. Niemeyer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ewog-mds.org</url>
    <description>Homepage of the EWOG-MDS-Study Group</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Charlotte Niemeyer, MD</investigator_full_name>
    <investigator_title>Prof. Dr. Charlotte Niemeyer, MD</investigator_title>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>JMML</keyword>
  <keyword>EWOG-MDS</keyword>
  <keyword>Myelodysplastic Syndromes (MDS)</keyword>
  <keyword>Juvenile Myelomonocytic Leukemia (JMML)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

